Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia

Cancer Genomics - Proteomics

MICHAEL MEDINGER¹  JAKOB PASSWEG²  CLAUDIA LENGERKE² 

[1] ivision of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerlandivision of Internal Medicine, Department of Medicine, University Hospital Basel, Basel, Switzerlandivision of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerlandivision of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerlandivision of Internal Medicine, Department of Medicine, University Hospital Basel, Basel, Switzerlandivision of Internal Medicine, Department of Medicine, University Hospital Basel, Basel, Switzerlandivision of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerlandivision of Internal Medicine, Department of Medicine, University Hospital Basel, Basel, Switzerland;ivision of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerlandivision of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerlandivision of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerland

关键词: Acute myeloid leukemia;    mutations;    targeted therapies;    tyrosine kinase inhibitors;    review;   

DOI  :  

来源: Delinasios GJ CO

【 摘 要 】

Acute myeloid leukemia (AML) is a biologically complex and molecularly and clinically heterogeneous disease, and its incidence increases with age. Cytogenetics and mutation testing remain important prognostic tools for treatment after induction therapy. The post-induction treatment is dependent on risk stratification. Despite rapid advances in determination of gene mutations involved in the pathophysiology and biology of AML, and the rapid development of new drugs, treatment improvements changed slowly over the past 30 years, with the majority of patients eventually experiencing relapse and dying of their disease. Allogenic hematopoietic stem cell transplantation remains the best chance of cure for patients with intermediate- or high-risk disease. This review gives an overview about advances in prognostic markers and novel treatment options for AML, focusing on new prognostic and probably therapeutic mutations, and novel drug therapies such as tyrosine kinase inhibitors.

【 授权许可】

Unknown